Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Cancer-Critical Genes I: Proto-oncogenes

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Same author

Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia.

Haematologica·2026

Same author

B-cell precursor acute lymphoblastic leukaemia with <i>IGH::CEBP</i> rearrangement: what have we learnt over the years?

Haematologica·2026

Same author

Single-cell multiomic atlas of healthy pediatric bone marrow reveals age-dependent differences in lineage differentiation driven by stromal signaling.

Nature immunology·2026

Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026

Same author

The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.

Blood·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Targeting oncogenes with siRNAs.

Olaf Heidenreich¹

¹Newcastle University, Northern Institute for Cancer Research, Medical School, Newcastle upon Tyne, UK.

Methods in Molecular Biology (Clifton, N.J.)

|March 24, 2009

Summary

Targeting cancer with RNA interference (RNAi) offers a specific approach to combatting tumors and preventing relapse. This method utilizes small interfering RNAs (siRNAs) to silence oncogenes, overcoming limitations of traditional chemotherapy.

Area of Science:

Oncology
Molecular Biology
Gene Therapy

Background:

Current cancer chemotherapies lack tumor cell specificity, causing severe side effects and failing to eliminate cancer stem cells, leading to relapse.
Oncogenes, exclusively expressed in cancer cells, present potential targets for specific therapeutic strategies, but their roles are often unknown.
Oncogenic transcription factors are typically undruggable with conventional small molecule drugs.

Purpose of the Study:

To explore oncogene-specific RNA interference (RNAi) as a novel therapeutic strategy for cancer.
To analyze oncogene functions directly within the tumor microenvironment using RNAi.
To investigate the potential of RNAi for targeting oncogenic transcription factors, expanding cancer-specific therapeutic targets.

Main Methods:

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Discussion of rationales and practical aspects of targeting oncogenes with small interfering RNAs (siRNAs).
Focus on the application of RNA interference in hematopoietic cells, which are challenging to transfect.
Addressing the challenge of systemic siRNA/shRNA delivery for effective therapeutic application.

Main Results:

RNA interference provides a method for analyzing oncogene functions in vivo.
RNAi-based strategies can potentially target previously undruggable oncogenic transcription factors.
Successful systemic delivery of siRNA/shRNA is crucial for advancing RNAi therapeutics.

Conclusions:

Oncogene-specific RNA interference offers a promising avenue for developing more efficient and specific cancer therapies.
Overcoming delivery challenges, particularly in hematopoietic cells, will be key to realizing the full potential of RNAi in cancer treatment.
RNAi represents a significant advancement in targeting cancer-specific mechanisms and overcoming therapeutic resistance.